NEURONTIN (gabapentin) by Pfizer is unknown. First approved in 2002.
Drug data last refreshed 9h ago
NEURONTIN (gabapentin) is an oral tablet antiepileptic drug (AED) approved by the FDA on May 24, 2002, for the treatment of epilepsy. Although structurally related to GABA, gabapentin's exact mechanism of action remains unclear; it binds with high affinity to the α2δ subunit of voltage-activated calcium channels, but the relationship between this binding and therapeutic efficacy is not fully understood. NEURONTIN is a mature, widely-used antiepileptic agent that serves as a foundational option in seizure management, though it competes in a crowded landscape of newer and alternative AED mechanisms.
unknown. Gabapentin is structurally related to the neurotransmitter gamma-aminobutyric acid (GABA) but has no effect on GABA binding, uptake, or degradation. In vitro studies have shown that gabapentin binds with high-affinity to the α2δ subunit of voltage-activated calcium channels; however, the…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
A Study on Ketoprofen Lysine Salt (KLS) + Gabapentin (GABA) vs KLS to Investigate Their Pharmacodynamic in Healthy Males
A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients
Efficacy of Gabapentin vs. Placebo for Adjuvant Pain Control Following Acute Rib Fractures
Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain
Worked on NEURONTIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moNEURONTIN's mature, generic-competitive status and late-lifecycle positioning create limited traditional brand management and field sales roles; career opportunities are concentrated in generic manufacturers, authorized generics programs, and specialty distributor networks rather than primary innovation-stage functions. Relevant roles include generic product managers, health economics and reimbursement specialists, and medical affairs professionals focused on cost-effectiveness and payer access strategies. Currently, zero open positions are linked to NEURONTIN development or commercialization according to the provided data.